Evaluation of a new immunochromatographic assay for rapid identification of influenza A, B, and A(H1N1)2009 viruses

Keiko Mitamura · Chiharu Kawakami · Hideaki Shimizu · Takashi Abe · Yasushi Konomi · Yuki Yasumi · Masahiko Yamazaki · Masataka Ichikawa · Norio Sugaya

Received: 18 September 2012 / Accepted: 3 December 2012 / Published online: 20 December 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract We evaluated Clearline Influenza A/B/(H1N1) 2009, a new multi-line immunochromatographic assay for rapid detection of antigens of influenza A (Flu A), B (Flu B), and A(H1N1)2009 viruses. Clearline detected Flu A, Flu B, and A(H1N1)2009 viruses with a detection limit of $4.6 \times 10^3$ to $7.5 \times 10^4$ pfu/assay. The sensitivity and specificity of detection of influenza virus by Clearline, using RT-PCR as reference standard, were determined for A(H1N1)2009, Flu A, and Flu B, in nasopharyngeal aspirate, nasopharyngeal swab, and self-blown nasal discharge specimens. Sensitivity for nasopharyngeal aspirate specimens was: A(H1N1)2009 = 97.3 %, Flu A = 94.5 %, and Flu B = 96.8 %, and specificity was Flu A = 99.1 % and Flu B = 100 %. Sensitivity for nasopharyngeal swab specimens was: A(H1N1)2009 = 91.9 %, Flu A = 92.8 %, and Flu B = 100 %, and specificity was Flu A = 98.2 % and Flu B = 100 %. Sensitivity for self-blown nasal discharge specimens was: A(H1N1)2009 = 75.7 %, Flu A = 86.5 %, and Flu B = 76.2 %, and specificity was Flu A = 98.4 % and Flu B = 100 %. Sensitivity and specificity of Clearline were sufficient for nasopharyngeal aspirate and swab specimens. For self-blown nasal discharge specimens, sensitivity was lower than for nasopharyngeal aspirates and nasopharyngeal swabs. The sensitivity of Clearline for A(H1N1)2009 was good even 6 h after the onset of symptoms. These findings suggest that Clearline may be useful for early clinical diagnosis of influenza.

Keywords Influenza virus · A(H1N1)2009 · Rapid diagnosis · Immunochromatography

Introduction

Seasonal and pandemic influenza are a major burden on health and the economy. New antivirals, for example neuraminidase inhibitors, have recently become available for management of influenza [1, 2]. Treatment and infection-control strategies are more effective when management is started at an early stage of illness and epidemics, so accurate and rapid diagnosis of influenza are very important for appropriate use of antivirals and for infection control. Although rapid influenza diagnostic tests (RIDTs) help early diagnosis of influenza and also detect A(H1N1) 2009 virus as Flu A, RIDTs cannot distinguish A(H1N1) 2009 from seasonal Flu A and the sensitivity of currently
available RIDTs was reported to be lower than for viral culture or RT-PCR, especially during the A(H1N1)2009 virus pandemic [3–5]. In this study, we evaluated the clinical usefulness of the Clearline Influenza A/B/ (H1N1)2009 test (Alere Medical, Tokyo, Japan), a new multi-line immunochromatographic assay for rapid detection of antigens of the Flu A, Flu B, and A(H1N1)2009 viruses.

Materials and methods

Basic evaluation

Detection limit

Ten vaccine strains and clinical isolates of influenza (Yokohama Institute of Public Health, Yokohama, Japan) [6] were used in this evaluation (Table 1). Viral titer was determined by plaque assays, and isolates were diluted serially in phosphate-buffered saline. A 100-μL aliquot of each viral suspension was mixed with 300 μL diluent, provided in the Clearline kit, and the mixture was then tested with Clearline. The detection limit was determined on the basis of Clearline results for different dilutions of each suspension.

Clinical evaluation

Clinical specimens

Three-hundred and thirty nasopharyngeal swab specimens and 336 nasopharyngeal aspirate specimens were collected simultaneously from 336 patients, including both children and adults, with influenza-like illness (upper respiratory symptoms and/or fever) at two hospitals and four clinics (four pediatric, one internal medicine, and one pediatric/ internal medicine) in Japan during the 2010/2011 influenza season (December 2010 to March 2011). Duration of fever was recorded by interview with patients. Another set of 268 patients with influenza like illness (upper respiratory symptoms and/or fever) was asked to blow nasal mucus into a collection film to furnish self-blown nasal discharge specimens. The results from the two patient cohorts were compared. The study protocol was approved by the ethics committee of Eiju General Hospital. All subjects provided informed consent to participate in this study.

Nasopharyngeal aspirate and self-blown nasal discharge specimens were tested with Clearline and with Espline influenza A&B–N (Fujirebio, Tokyo, Japan), without dilution by viral transport media. These specimens were sampled using swabs; the swabs were soaked in 1.5 mL viral transport medium and stored at −80 °C for RT-PCR as the reference assay. One nasopharyngeal swab collected from each patient was tested with Clearline.

Methods of measurement

Rapid diagnostic tests Clearline Influenza A/B (H1N1)2009 has three test lines, for differentiation of Flu A, Flu B, and A(H1N1)2009 viruses, and a control line [7]. Testing was performed in accordance with the manufacturer’s instructions. A specimen-collection swab provided in the kit was used to obtain the specimen. The swab containing the specimen was placed directly in a dedicated soft plastic tube containing 300 μL diluent provided in the kit. The swab was then rotated at least 5 times, squeezed against the interior wall of the tube, and pulled up while squeezing to extract the liquid from the swab. A test strip was inserted into the tube to start the reaction. After 10–15 min, the appearance of red–purple lines on the strip was assessed in accordance with the criteria in the manufacturer’s instructions.

Espline Influenza A&B–N is a lateral flow RIDT using enzyme immunoassay to differentiate Flu A and Flu B [8]. Testing was performed in accordance with the manufacturer’s instructions.

RT-PCR The specimens were subjected to multiplex RT-PCR. A PCR sample was extracted from 200 μL of each stored suspension by use of the QIAamp® Min Elute Virus Spin Kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer’s instructions. The multiplex RT-PCR was performed with Seeplex RV 12 ACE Detection kit and the combined Supplement procedure for detection and characterization of swine H1 influenza A virus provided by manufacturer (Seegene, Seoul, Korea), to detect A(H1N1) 2009, Flu A, and Flu B [9–11]. The HA gene of Flu A virus other than A(H1N1)2009 virus was detected, by use of real-time RT-PCR, to characterize subtype [12].

Table 1 Detection limit of Clearline for influenza virus strains

| Virus strain                | Detection limit (pfu/assay) |
|----------------------------|-----------------------------|
| A/California/7/2009 (H1N1)2009 | $5.3 \times 10^4$          |
| A/Yokohama/29/2010 (H1N1)2009    | $5.6 \times 10^3$          |
| A/Yokohama/1000/2009 (H1N1)2009    | $4.6 \times 10^3$          |
| A/New Caledonia/20/99 (H1N1)     | $5.8 \times 10^4$          |
| A/Yokohama/119/2009 (H1N1)       | $2.8 \times 10^4$          |
| A/Yokohama/22/2002 (H1N2)        | $3.2 \times 10^4$          |
| A/Hiroshima/52/2005 (H3N2)       | $2.1 \times 10^4$          |
| A/Yokohama/72/2010 (H3N2)        | $7.5 \times 10^4$          |
| B/Shanghai/361/2002 (Yamagata lineage) | $1.7 \times 10^4$          |
| B/Malaysia/2506/2004 (Victoria lineage) | $1.4 \times 10^4$          |
Statistical analysis

SPSS statistics 20 (Japan IBM, Japan) was used for statistical analysis. A p value of less than 0.05 was considered statistically significant.

Results

Basic evaluation

Detection limit of Clearline

The detection limit of Clearline was $4.6 \times 10^3$ to $7.5 \times 10^4$ pfu/assay for ten influenza virus strains including A(H1N1)2009 (Table 1).

Clinical evaluation

Sensitivity and specificity

Among the 336 nasopharyngeal aspirate specimens, multiplex RT-PCR detected A(H1N1)2009 virus in 149 specimens, Flu A strains other than A(H1N1)2009 in 73 specimens, and Flu B in 31 specimens. All Flu A strains other than A(H1N1)2009 were confirmed to be H3 strains (Flu A (H3)).

As Tables 2 and 3 show, the sensitivity of Clearline compared with multiplex RT-PCR for A(H1N1)2009, Flu A (H3), and Flu B was 97.3 % (145/149), 94.5 % (69/73), and 96.8 % (30/31), respectively. The specificity was 99.1 % (113/114) for type A influenza virus and 100 % (305/305) for Flu B. Among RT-PCR-confirmed A(H1N1)2009-positive specimens, nine samples were positive only on the A(H1N1)2009 test line of Clearline but negative on the Flu A test line. The corresponding sensitivity of Espline compared with multiplex RT-PCR was almost same as for Clearline. For both Clearline and Espline, sensitivity for self-blown nasal discharge specimens for A(H1N1)2009 was lower than for nasopharyngeal aspirate and nasopharyngeal swab specimens ($p < 0.001$ for each).

Effect of time after onset of fever on the sensitivity of Clearline

The effect of time after onset of fever on the sensitivity of Clearline and Espline is listed in Table 4 for nasopharyngeal aspirates and swabs confirmed positive by multiplex RT-PCR, for the 248 specimens for which time from onset of fever was known. The sensitivity of Clearline and Espline was more than 85 % for specimens collected more than 6 h after onset. Within 6 h of onset, the sensitivity of Clearline for A(H1N1)2009 was high (100 % for nasopharyngeal aspirate and 88.2 % for nasopharyngeal swab) although the sensitivity of Clearline for Flu A(H3) and of Espline for Flu A(H3) and A(H1N1)2009 was relatively low (80.0–82.4 %).

Discussion

The performance of RIDTs for patients with influenza depends on viral load [13, 14]. Detection limits of currently available RIDTs have been reported to differ widely among viral strains or kits, ranging from approximately $10^3$ to $10^5$ pfu/assay or $10^3$ to $>10^6$ TCID$_{50}$/assay for seasonal influenza, A(H1N1)2009, and avian influenza [6, 15]. In this study, the detection limits of Clearline were approximately $10^4$ pfu/assay for Flu A and Flu B, and from $4.6 \times 10^3$ to $5.3 \times 10^4$ pfu/assay for A(H1N1)2009. The detection limit of Clearline was fairly consistent, irrespective of viral strain, and was equivalent to those previously reported for conventional diagnostic kits [6].

In our previously study, the sensitivity of Espline for nasopharyngeal aspirates compared with viral culture was 95.4 % (125/131) for Flu A (not including A(H1N1)2009)
and 91.2 % (52/57) for Flu B [8]. Cheng et al. [13] reported low sensitivity of Espline for A(H1N1)2009 (62 %), but the specimens in their study were diluted with viral transport medium. In our study, the sensitivity of Clearline and Espline for Flu A (H3) in nasopharyngeal aspirates using multiplex RT-PCR as reference standard was 94.5 % (69/73) and 94.5 % (69/73), respectively, which was high, and similar to that in our previous report. The specimens were tested directly, without dilution with viral transport medium. If test methods are adjusted, sensitivity of RIDTs may

### Table 2  Comparison of Clearline and Espline with multiplex RT-PCR for 3 types of specimen

| Specimen types | RIDTs    | Sensitivity          | Specificity         |
|----------------|----------|----------------------|---------------------|
|                |          | A(H1N1)2009          | A(H3)               | Type B               | Type A               | Type B               |
| Nasopharyngeal aspirate (n = 336) | Clearline | 97.3 % (94.7–99.9) | 94.5 % (86.6–98.5) | 96.8 % (83.3–99.9) | 99.1 % (97.4–100) | 100.0 % (100–100) |
|                | Espline  | 91.9 % (87.6–96.3) | 94.5 % (86.6–98.5) | 100.0 % (88.8–100) | 100.0 % (100–100) | 99.0 % (97.9–100) |
| Nasopharyngeal swab (n = 330) | Clearline | 91.9 % (87.6–96.3) | 92.8 % (83.9–96.3) | 100.0 % (100–100) | 98.2 % (95.8–100) | 100.0 % (100–100) |
|                | Espline  | 75.7 % (67.4–84.0)* | 86.5 % (71.2–95.5) | 76.2 % (52.8–91.8) | 98.4 % (96.3–100) | 100.0 % (100–100) |
| Self-blown nasal discharge (n = 268) | Clearline | 72.8 % (64.2–81.4)* | 97.3 % (85.8–99.9) | 76.2 % (52.8–91.8) | 100.0 % (100–100) | 100.0 % (100–100) |
|                | Espline  | 72.8 % (64.2–81.4)* | 97.3 % (85.8–99.9) | 76.2 % (52.8–91.8) | 100.0 % (100–100) | 100.0 % (100–100) |

Ranges in parentheses are 95 % confidence intervals

*p < 0.001: compared with both nasopharyngeal aspirate and swab specimens (chi-squared test)
be sufficient for practical use. The corresponding figures for A(H1N1)2009 were 97.3% (145/149) for Clearline and 91.9% (137/149) for Espline. Although these values are not statistically significantly different, direct comparison shows Clearline was able to detect more A(H1N1)2009 cases than Espline (nine cases were positive by Clearline but negative by Espline, and one was negative by Clearline but positive by Espline) because of the high sensitivity of the A(H1N1)2009 test line of Clearline. Choi et al. [7] also reported relatively high sensitivity of the A(H1N1)2009 test line compared with the Flu A test line for nasopharyngeal swab specimens. If the A(H1N1)2009 line is negative for specimens with positive Flu A test line, this may suggest positive Flu A(H3) during interpandemics.

In this study, we collected two types of specimen simultaneously from 330 patients, and compared the sensitivity directly for nasopharyngeal aspirations and nasopharyngeal swabs. The sensitivity of Clearline was no different for nasopharyngeal swab and nasopharyngeal aspiration specimens.

Self-blown nasal discharge is a type of specimen recently approved for use in RIDTs in Japan. This type of specimen may reduce the burden of sampling—it is possible to collect specimens without medical equipment and from patients who must avoid injury to the nasal cavity. One limitation of this study is that self-blown nasal discharge specimens were obtained from a patient population different from that from which the nasopharyngeal aspirates and swabs were obtained, making direct comparison of sensitivity between specimen types somewhat more difficult. Although sensitivity of both Clearline and Espline for self-blown nasal discharges was more than 72%, this was lower than for nasopharyngeal aspirates and swabs (p < 0.001). Physicians should be aware that the use of self-blown nasal discharge specimens may reduce the sensitivity of the assay, and should conduct specimen collection carefully to obtain an ample volume.

This study was conducted at four pediatric sites, one internal medicine site, and one pediatric/ internal medicine site. Sensitivity and specificity were not statistically different among the 3 types of site. Further study may be necessary to determine whether patient age affects the sensitivity of RIDTs.

During the A(H1N1) influenza pandemic in 2009, deaths due to influenza were less common in Japan than in other countries. Use of anti-influenza agents from an early stage of infection is believed to be one reason for this lower mortality in Japan [16]. Analysis of Japanese pediatric patients hospitalized for respiratory disorders due to A(H1N1)2009 in this pandemic revealed 87.5% developed dyspnea within 24 h of onset of fever [17]. It is recommended antivirals are started as soon as possible for patients with severe or progressive influenza, before the result from influenza testing is received [2]. It is, thus, important to promptly and correctly diagnose influenza and start treatment with anti-influenza agents [16]. However, there was a tendency toward lower accuracy of RIDTs on the first day of illness [5]. Our results showed sensitivity within 6 h of the onset of fever was relatively low for A(H1N1)2009 for Espline and for Flu A(H3) but that the sensitivity of Clearline for A(H1N1)2009 was high within 6 h of onset and for specimens collected after 6 h from onset. High sensitivity of the A(H1N1)2009 test line may contribute to the sensitivity within 6 h of onset of fever.

The cost of Clearline is equivalent to that of the other tests, when comparing the list prices (the price for Clearline is within the range of list price for other test, approximately US$ 11–16 per test; exchange rate ¥80/ US$). So Clearline has the value of detecting the A(H1N1)2009 virus separately from the Flu A virus at a cost equivalent to those of the other conventional tests.

In conclusion, Clearline may be expected to help physicians to diagnose influenza promptly and detect A(H1N1)2009 virus separately from the Flu A(H3) virus in the clinical setting. Further studies may be necessary to evaluate the factors that affect the sensitivity of RIDTs.

Acknowledgments This study was financially supported by Alere Medical Co., Ltd. (Japan).

Conflict of interest Dr Sugaya has received honoraria for lectures from Shionogi and Chugai. None of the other authors have any potential conflicts of interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156:512–24.

2. WHO guidelines for pharmacological management of pandemic influenza A(H1N1)2009 and other influenza viruses. Revised February 2010. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.

3. Centers for Disease Control and Prevention (CDC) (2009) Interim Guidance for the Detection of Novel Influenza A Virus Using Rapid Influenza Diagnostic Tests. http://www.cdc.gov/h1n1flu/guidance/rapid_testing.htm.

4. Centers for Disease Control and Prevention (CDC). Performance of rapid influenza diagnostic tests during two school outbreaks of 2009 pandemic influenza A (H1N1) virus infection - Connecticut, 2009. MMWR Morbid. Mortal. Wkly. Rep. 2009;58:1029–32.

5. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012;156:500–11.

6. Kawakami C, Saikusa M, Watanabe T, Shimizu H, Yamazaki M, Ichikawa M, et al. A comparison of responsiveness and sensitivity of rapid diagnostic kits for influenza A (H1N1) 2009 virus. Kansenshogaku Zasshi. 2011;85:143.

7. Choi YJ, Kim HJ, Park JS, Oh MH, Nam HS, Kim YB, et al. Evaluation of new rapid antigen test for detection of pandemic influenza A/H1N1 2009 virus. J Clin Microbiol. 2010;48:2260–2.

8. Mitamura K, Yamazaki M, Ichikawa M, Kimura K, Kawakami C, Shimizu H, et al. Evaluation of an immunochromatography test using enzyme immunoassay for rapid detection of influenza A and B viruses. Kansenshogaku Zasshi. 2004;78:597–603.

9. Lee CS, Kang BK, Lee DH, Lyou SH, Park BK, Ann SK, et al. One-step multiplex RT-PCR for detection and subtyping of swine influenza H1, H3, N1, N2 viruses in clinical samples using a dual priming oligonucleotide (DPO) system. J Virol Methods. 2008;151:30–4.

10. Hwang Y, Kim K, Lee M. Evaluation of the efficacies of rapid antigen test, multiplex PCR, and real-time PCR for the detection of novel influenza A(H1N1) virus. Korean J Lab Med. 2010;30:147–52.

11. Kim SR, Ki CS, Lee NY. Rapid detection and identification of 12 respiratory viruses using a dual priming oligonucleotide system-based multiplex PCR assay. J Virol Methods. 2009;156:111–6.

12. WHO Global Influenza Surveillance Network. 2.I Molecular identification of influenza isolates. Manual for the laboratory diagnosis and virological surveillance of influenza. Switzerland: WHO Press; 2011. p. 83–96.

13. Cheng PK, Wong KK, Mak GC, Wong AH, Ng AY, Chow SY, et al. Performance of laboratory diagnostics for the detection of influenza A(H1N1)v virus as correlated with the time after symptom onset and viral load. J Clin Virol. 2010;47:182–5.

14. Ganzenmueller T, Kluba J, Hilfrich B, Puppe W, Verhagen W, Heim A, et al. Comparison of the performance of direct fluorescent antibody staining, a point-of-care rapid antigen test and virus isolation with that of RT-PCR for the detection of novel 2009 influenza A(H1N1) virus in respiratory specimens. J Med Microbiol. 2010;59:713–7.

15. Sakai-Tagawa Y, Ozawa M, Tamura D, Le QM, Nidom CA, Sugaya N, et al. Sensitivity of influenza rapid diagnostic tests to H1N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol. 2010;48:2872–7.

16. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A(H1N1)2009 mortality associated with early neuraminidase inhibitor in Japan: analysis of 100 hospitalized children. J Infect. 2011;63:288–94.

17. Matsui T, Iwata C, Katsunuma T, Nanbu M, Okada K, Kondo N. The second expedited survey of patients hospitalized for influenza—a comparison of patients presenting with respiratory symptoms without underlying diseases. Jpn J Pediatr Allergy Clin Immunol. 2010;24:115–66.